LRMR
Larimar Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$358.40M
P/E Ratio
—
EPS
$-2.12
Beta
0.91
52W High
$6.42
52W Low
$1.80
50-Day MA
$4.38
200-Day MA
$4.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases. The company is headquartered in Bala Cynwyd, Pennsylvania.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-172.10M |
| Operating Margin | 0.00% |
| Return on Equity | -109.80% |
| Return on Assets | -56.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.51 |
| Price-to-Book | 2.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $103.88M |
| Float | $59.99M |
| % Insiders | 1.10% |
| % Institutions | 85.55% |
Historical Volatility
HV 10-Day
82.20%
HV 20-Day
71.32%
HV 30-Day
60.43%
HV 60-Day
65.17%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($15.88 target)
1
Strong Buy10
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026